Abstract
Downbeat nystagmus (DBN) is the most frequent form of acquired persisting fixation nystagmus. It is hypothesized to occur when physiological inhibitory cerebellar input, namely of the flocculus, to the vestibular nuclei is inhibited. The second most frequent form of acquired nystagmus is upbeat nystagmus (UBN). UBN is probably caused by an imbalance of vertical vestibulo-ocular reflex tone. GABA-ergic substances like baclofen have been used to treat DBN and UBN, but they have had only moderate success. Animal experiments have shown that aminopyridines [3,4-diaminopyridine (3,4-DAP) and 4-aminopyridine (4-AP)], nonselective blockers of the Kv family of voltage-gated potassium channels, increase Purkinje-cell (PC) excitability. It was assumed that such enhancement of PC activity could restore to normal levels the inhibitory influence of the cerebellar cortex on vertical eye movements. On the basis of these assumptions, we evaluated the efficacy and underlying mechanisms of aminopyridines in DBN and UBN as well as in another cerebellar disorder with an impaired PC function: episodic ataxia type 2 (EA2), which is caused by mutations of the PQ-calcium channel. In a placebo-controlled trial on 17 patients we demonstrated that 3,4-DAP...Continue Reading
Citations
May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karina Alviña, Kamran Khodakhah
May 28, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karina Alviña, Kamran Khodakhah
Aug 13, 2014·BioMed Research International·Hsin-Te HsuWun-Chang Ko
May 7, 2014·Multiple Sclerosis International·Luca ProsperiniCarlo Pozzilli
Apr 22, 2016·Neurological Research·Hashem Haghdoost-YazdiMahmud Alipour Heidari
Jan 6, 2015·International Neurourology Journal·Michael StruppRaphaela Waidelich
Sep 2, 2016·Therapeutic Advances in Neurological Disorders·Hiroshi Mitoma, Mario Manto
Dec 21, 2017·The Cerebellum·Aasef G Shaikh, David S Zee
Mar 6, 2018·The Cochrane Database of Systematic Reviews·Fiona J RoweHelen Rodgers
Nov 6, 2009·The Cerebellum·Antoni Matilla-DueñasPilar Latorre
Nov 26, 2010·Current Opinion in Neurology·Caroline Tilikete, Alain Vighetto
Jul 16, 2009·Expert Opinion on Pharmacotherapy·Rebecca Jane McLean, Irene Gottlob
Feb 23, 2012·Current Neurology and Neuroscience Reports·Rebecca Jane McLeanFrank Antony Proudlock
Jul 26, 2013·Journal of Neurology·Aasef G ShaikhDominik Straumann
Jun 12, 2014·Movement Disorders Clinical Practice·Harini Sarva, Vicki Lynn Shanker
Nov 26, 2010·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Matthew J Thurtell, R John Leigh
Apr 24, 2015·Annals of the New York Academy of Sciences·Michael StruppThomas Brandt
Mar 25, 2011·Journal of Neurology·Roman SchnieppKlaus Jahn
Dec 11, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Luca ProsperiniCarlo Pozzilli
Oct 7, 2015·BMC Complementary and Alternative Medicine·Chung-Hung ShihWun-Chang Ko
Nov 9, 2010·Journal of Neurology·T SanderC Helmchen
Nov 22, 2020·Journal of Neurology·Ji-Hyun ChoiBeomseok Jeon
Jul 20, 2010·European Journal of Pharmacology·Iran GoudarziMahyar Janahmadi
Aug 31, 2021·Current Opinion in Ophthalmology·Tu M TranCollin M McClelland
May 5, 2011·Behavioural Brain Research·Hashem Haghdoost-YazdiFatemeh Vaezi
Nov 23, 2021·Frontiers in Neurology·Taylor J BoschArun Singh